These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11237358)

  • 1. The determination of phosphorus in Haemophilus influenzae type b conjugate vaccines by inductively coupled plasma-atomic emission spectrometry.
    Swartz LA; Progar JJ; May JC
    Biologicals; 2000 Dec; 28(4):227-31. PubMed ID: 11237358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the saccharide content and stability of the first WHO International Standard for Haemophilus influenzae b capsular polysaccharide.
    Mawas F; Bolgiano B; Rigsby P; Crane D; Belgrave D; Corbel MJ
    Biologicals; 2007 Oct; 35(4):235-45. PubMed ID: 17337205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine.
    Guo YY; Anderson R; McIver J; Gupta RK; Siber GR
    Biologicals; 1998 Mar; 26(1):33-8. PubMed ID: 9637747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability testing in Haemophilus influenzae type b conjugate vaccines.
    Klug B
    Dev Biol Stand; 1996; 87():263-7. PubMed ID: 8854026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International collaborative study for establishment of the 2nd WHO International Standard for Haemophilus influenzae type b polysaccharide.
    Mawas F; Burkin K; Dougall T; Saydam M; Rigsby P; Bolgiano B;
    Biologicals; 2015 Nov; 43(6):492-503. PubMed ID: 26298195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An NMR spectroscopic identity test for the control of the capsular polysaccharide from Haemophilus influenzae type b.
    Lemercinier X; Jones C
    Biologicals; 2000 Sep; 28(3):175-83. PubMed ID: 10964444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endotoxin content in Haemophilus influenzae type b vaccine.
    Ochiai M; Kataoka M; Toyoizumi H; Yamamoto A; Kamachi K; Arakawa Y; Kurata T; Horiuchi Y
    Jpn J Infect Dis; 2004 Apr; 57(2):58-9. PubMed ID: 15118211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIB.
    Xu Q; Klees J; Teyral J; Capen R; Huang M; Sturgess AW; Hennessey JP; Washabaugh M; Sitrin R; Abeygunawardana C
    Anal Biochem; 2005 Feb; 337(2):235-45. PubMed ID: 15691503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
    Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
    Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide.
    Sturgess AW; Rush K; Charbonneau RJ; Lee JI; West DJ; Sitrin RD; Hennessy JP
    Vaccine; 1999 Mar; 17(9-10):1169-78. PubMed ID: 10195629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.